Drug reference

Eltrombopag

Colony-Stimulating Factor · Agent for Cytopenias

Also known as PROMACTA

Colony-Stimulating FactorAgent for Cytopenias

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

11 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactionssee all 11 →

BerotralstatSevereDatabaseDDInter
CarfilzomibSevereDatabaseDDInter
EluxadolineSevereDatabaseDDInter
GrazoprevirSevereDatabaseDDInter

Mechanism

Eltrombopag is a small organic molecule that acts as a thrombopoietin receptor agonist. It binds specifically to the thrombopoietin receptor, mimicking the action of endogenous thrombopoietin. This action stimulates the proliferation and differentiation of megakaryocytes, leading to an increase in platelet production.

Indications

Immune thrombocytopenic purpura (ITP) in patients who have failed to respond to more conventional treatmentsChronic ITP in adult patients who had completed at least one prior treatment course and had severe thrombocytopeniasevere aplastic anemia (first-line in combination with immune suppression)chronic hepatitis C virus (HCV)–associated thrombocytopeniaimmune thrombocytopenia (ITP) with insufficient response to corticosteroids, immune globulin, or splenectomy

Dosing

Adult: Oral: Recommended starting dose is 30 g per day, titrated to 75 mg depending on platelet response.
Max dose: 75 mg daily

Side effects

Serious

Thromboembolic disease (if platelet count rises to very high levels)
portal vein thrombosis (in patients with advanced liver disease)
marrow fibrosis
rebound thrombocytopenia
increased risk of hepatic decompensation (in patients with chronic HCV receiving interferon and ribavirin)
hepatotoxicity